Dainippon Sumitomo Pharma
VC Fund
Osaka, Japan
Dainippon Sumitomo Pharma is a VC fund in Osaka focused on Health Care and Biotechnology. "Green Prism", the symbol of Dainippon Sumitomo Pharma Co., Ltd. is a motif in the design of the "Sun"-expressing a lively sense of energy, moving on toward tomorrow; "Light"-to convey the potential and hope of the future; and "Flower"-engendering the joyous and liberated sensation of basking in good health.A design crafted to embody preeminent research and development powers, a thorough support system, the spirit of challenge, and the other stances of Dainippon Sumitomo Pharma-a company bent on supplying all people with the strength to push on toward an even brighter tomorrow.Emanating from the symbol, furthermore, is the image of a network, steadily spreading out into the world.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 17%
Last updated:
For AI agents: llms.txt
Industries Dainippon Sumitomo Pharma invests in
Stages Dainippon Sumitomo Pharma invests in
Countries Dainippon Sumitomo Pharma invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Antony Loebel
|
|||
Hiroshi Noguchi
|
|||
Hiroshi Nomura
|
|||
Hitoshi Odagiri
|
|||
Masaru Ishidahara
|
|||
| See all 8 contacts → | |||
Investment Focus
Industry
- Health Care 5 (83%)
- Biotechnology 3 (50%)
- Medical 2 (33%)
- Medical Device 2 (33%)
- Pharmaceutical 2 (33%)
Stage
- Funding Round 2 (33%)
- Series A 1 (17%)
- Post-IPO Debt 1 (17%)
- Debt Financing 1 (17%)
- Post-IPO Equity 1 (17%)
Country
- Japan 3 (50%)
- United States 2 (33%)
- United Kingdom 1 (17%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Antony Loebel
Executive Officer & Head of Global Clinical Development
|
Executive Officer & Head of Global Clinical Development | Total investments: 0 | Find email | |
|
Hiroshi Noguchi
Senior Executive Vice President Drug Research; Drug Development
|
Senior Executive Vice President Drug Research; Drug Development | Total investments: 0 | Find email | |
|
Hiroshi Nomura
EVP External Affairs; Corporate Secretariat & Industry Affairs
|
EVP External Affairs; Corporate Secretariat & Industry Affairs | Total investments: 0 | Find email | |
|
Hitoshi Odagiri
Senior Executive Officer & Executive Director, Sales & Marketing
|
Senior Executive Officer & Executive Director, Sales & Marketing | Total investments: 0 | Find email | |
|
Masaru Ishidahara
Senior Executive Officer Corporate Governance; Personnel
|
Senior Executive Officer Corporate Governance; Personnel | Total investments: 0 | Find email | |
| See all 8 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Roivant Sciences
|
Roivant Sciences is a biopharmaceutical company focused on completing the development of promising late-stage drug candidates.Roivant’s mission is to reduce the time and cost of developing new medicines for patients and to share those savings with the healthcare system. Roivant does this by building Vants - nimble, entrepreneurial biotech andhealthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying the technology. In addition to its biopharmaceutical subsidiaries, Roivant also builds technology-focused Vants focused on improving the process of developing and commercializing medicines. | $200M / Post-IPO Equity / Oct 01, 2021 | |
Myovant Sciences
|
Myovant Sciences is to deliver innovative women's health and prostate cancer solutions by efficiently advancing new medicines to market. | $200M / Post-IPO Debt / Aug 05, 2020 | |
Drawbridge Health
|
Founded in 2015 by GE Ventures and GE Healthcare, Drawbridge Health is a privately held healthcare technology company that is focused on reinventing the blood sampling paradigm, enabling comfortable and convenient blood sample collection anytime and anywhere. Drawbridge has both internally generated IP and the exclusive license to GE’s substantialblood stabilization chemistry IP portfolio. | Debt Financing / Jul 24, 2019 | |
AlphaNavi Pharma
|
AlphaNavi Pharma specializes in the research and development of new drugs. | $127.6M / Series A / Apr 05, 2019 | |
Healios
|
Healios aims to commercialize the world’s first pharmaceutical hiPSC derived RPE cell transplantation for treatment of AMD in collaboration with RIKEN, one of the leading research institutes in Japan. The goal of this therapy is to promote the regeneration of retinal function and, consequently, to improve visual function in those affected withretinal degenerative diseases.The significance of the total raised capital fortifies the company’s momentum in the development of therapeutics utilizing the Nobel Prize-winning hiPSC technology and attests its uncompromising commitment to making groundbreaking strides in the field of regenerative medicine. | $425.2M / Oct 08, 2013 | |
FunPep
|
FunPep is an Industry-university collaboration bioventure company. |
Co-Investors
Patient Square Capital
2 deals together
Bio-sight Capital
1 deal together
Dogan
1 deal together
Eventide
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Dainippon Sumitomo Pharma invest in?
Dainippon Sumitomo Pharma invests primarily in Health Care, Biotechnology and Medical startups, most often at Funding Round and Series A stage. Most of the 6 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Dainippon Sumitomo Pharma?
Public channels for Dainippon Sumitomo Pharma include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Dainippon Sumitomo Pharma?
The team at Dainippon Sumitomo Pharma includes Antony Loebel (Executive Officer & Head of Global Clinical Development), Hiroshi Noguchi (Senior Executive Vice President Drug Research; Drug Development) and Hiroshi Nomura (EVP External Affairs; Corporate Secretariat & Industry Affairs), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
